rituximab + idelalisib + venetoclax (Virginia Commonwealth University)

This drug refers to a specific triple-combination regimen evaluated in the Phase 1 RIVe-CLL/SLL trial (NCT03639324) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The regimen consists of rituximab, a CD20-targeting monoclonal antibody; idelalisib, a selective inhibitor of the PI3K delta isoform; and venetoclax, a BCL-2 inhibitor. Specifically, dose combination 1-2 in this trial context involves 100 mg once daily (QD) of idelalisib and 200 mg QD of venetoclax, administered alongside rituximab. The study, sponsored by Virginia Commonwealth University, aims to determine the recommended phase 2 dose (RP2D) for this combination, leveraging the synergistic effects of targeting B-cell surface antigens, intracellular signaling pathways, and apoptotic mechanisms.

Other names

dose combination 1-2-Virginia Commonwealth University-chronic lymphocytic leukemia-small lymphocytic lymphomaRIVe regimenRIVe combination